Vesicular Stomatitis Virus-Simian Retrovirus Type 2 Vaccine Protects Macaques from Detectable Infection and B-Cell Destruction

被引:5
|
作者
Gautam, Rajeev [1 ]
Iyer, Arun [3 ]
Hunter, Meredith [1 ]
Das, Arpita [1 ]
Williams, Tessa [2 ]
Dufour, Jason [2 ]
Apetrei, Cristian [1 ]
Kousoulas, K. Gus [3 ]
Marx, Preston A. [1 ]
机构
[1] Tulane Natl Primate Res Ctr, Div Microbiol, Covington, LA 70433 USA
[2] Tulane Natl Primate Res Ctr, Div Vet Med, Covington, LA 70433 USA
[3] Louisiana State Univ, Sch Vet Med, Div Biotechnol & Mol Med, Baton Rouge, LA 70803 USA
关键词
IMMUNE-DEFICIENCY-SYNDROME; PFIZER MONKEY VIRUS; CD4(+) T-CELLS; ENVELOPE GLYCOPROTEINS; PREDICTION SYSTEM; MEMBRANE-PROTEINS; RECOMBINANT; IMMUNIZATION; EXPRESSION; DISEASE;
D O I
10.1128/JVI.02523-10
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Natural infection with simian retrovirus (SRV) has long been recognized in rhesus macaques (RMs) and may result in an AIDS-like disease. Importantly, SRV infections persist as a problem in recently imported macaques. Therefore, there is a clear need to control SRV spread in macaque colonies. We developed a recombinant vesicular stomatitis virus (VSV)-SRV vaccine consisting of replication-competent hybrid VSVs that express SRV gag and env in separate vectors. The goal of this study was to assess the immunogenicity and protective efficacy of the VSV-SRV serotype 2 vaccine prime-boost approach in RMs. The VSV-SRV vector (expressing either SRV gag or env) vaccines were intranasally administered in 4 RMs, followed by a boost 1 month after the first vaccination. Four RMs served as controls and received the VSV vector alone. Two months after the boost, all animals were intravenously challenged with SRV-2 and monitored for 90 days. After the SRV-2 challenge, all four controls became infected, and viral loads (VLs) ranged from 106 to 108 SRV RNA copies/ml of plasma. Two animals in the control group developed simian AIDS within 7 to 8 weeks postinfection and were euthanized. Anemia and weight loss were observed in the remaining controls. During acute infection, severe B-cell depletion and no significant changes in T-cell population were observed in the control group. Control RMs with greater preservation of B cells and lower VLs survived longer. SRV-2 was undetectable in vaccinated animals, which remained healthy, with no clinical or biological signs of infection and preservation of B cells. Our study showed that the VSV-SRV vaccine is a strong approach for preventing clinically relevant type D retrovirus infection and disease in RMs, with protection of 4/4 RMs from SRV infection and prevention of B-cell destruction. B-cell protection was the strongest correlate of the long-term survival of all vaccinated and control RMs.
引用
收藏
页码:5889 / 5896
页数:8
相关论文
共 26 条
  • [21] Epstein-Barr Virus Infection of Cell Lines Derived from Diffuse Large B-Cell Lymphomas Alters MicroRNA Loading of the Ago2 Complex
    Ayoubian, Hiresh
    Ludwig, Nicole
    Fehlmann, Tobias
    Menegatti, Jennifer
    Groeger, Laura
    Anastasiadou, Eleni
    Trivedi, Pankaj
    Keller, Andreas
    Meese, Eckart
    Graesser, Friedrich A.
    JOURNAL OF VIROLOGY, 2019, 93 (03)
  • [22] DNA vaccination with the human immunodeficiency virus type 1 SF162ΔV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8+ T-cell-depleted rhesus macaques
    Cherpelis, S
    Shrivastava, I
    Gettie, A
    Jin, X
    Ho, DD
    Barnett, SW
    Stamatatos, L
    JOURNAL OF VIROLOGY, 2001, 75 (03) : 1547 - 1550
  • [23] In Silico Identification and Conservation Analysis of B-cell and T-Cell Epitopes of Hepatitis C Virus 3a Genotype Enveloped Glycoprotein 2 From Pakistan: A Step Towards Heterologous Vaccine Design
    Ikram, Aqsa
    Anjum, Sadia
    Tahir, Muhammad
    HEPATITIS MONTHLY, 2014, 14 (06)
  • [24] The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection
    Arieta, Christina M.
    Xie, Yushu Joy
    Rothenberg, Daniel A.
    Diao, Huitian
    Harjanto, Dewi
    Meda, Shirisha
    Marquart, Krisann
    Koenitzer, Byron
    Sciuto, Tracey E.
    Lobo, Alexander
    Zuiani, Adam
    Krumm, Stefanie A.
    Couto, Carla Iris Cadima
    Hein, Stephanie
    Heinen, Andre P.
    Ziegenhals, Thomas
    Liu-Lupo, Yunpeng
    Vogel, Annette B.
    Srouji, John R.
    Fesser, Stephanie
    Thanki, Kaushik
    Walzer, Kerstin
    Addona, Theresa A.
    Tureci, Ozlem
    Sahin, Ugur
    Gaynor, Richard B.
    Poran, Asaf
    CELL, 2023, 186 (11) : 2392 - +
  • [25] TH2-LIKE CD8+ T-CELLS SHOWING B-CELL HELPER FUNCTION AND REDUCED CYTOLYTIC ACTIVITY IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    MAGGI, E
    GIUDIZI, MG
    BIAGIOTTI, R
    ANNUNZIATO, F
    MANETTI, R
    PICCINNI, MP
    PARRONCHI, P
    SAMPOGNARO, S
    GIANNARINI, L
    ZUCCATI, G
    ROMAGNANI, S
    JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (02): : 489 - 495
  • [26] Protection from persistent infection with a bovine viral diarrhea virus (BVDV) type 1b strain by a modified-live vaccine containing BVDV types 1a and 2, infectious bovine rhinotracheitis virus, parainfluenza 3 virus and bovine respiratory syncytial virus
    Xue, Wenzhi
    Mattick, Debra
    Smith, Linda
    VACCINE, 2011, 29 (29-30) : 4657 - 4662